```html

Zoster‑Related Vertigo

What is Zoster‑related vertigo?

Vertigo is the sensation that you or your surroundings are spinning. When it occurs after an infection with the varicella‑zoster virus (VZV), the same virus that causes chickenpox and shingles, it is called zoster‑related vertigo (also known as shingles‑associated vestibular neuritis or herpes zoster oticus when the ear is involved). After the initial shingles rash heals, the virus can reactivate in the vestibular (balance) portions of the cranial nerves, producing dizziness, imbalance, nausea, and sometimes hearing loss.

Unlike classic vertigo caused by inner‑ear disorders such as benign paroxysmal positional vertigo (BPPV), zoster‑related vertigo stems from viral inflammation of the vestibular nerve or the inner ear structures. The condition is relatively uncommon—most adults who develop shingles never experience vertigo—but it can be disabling and, if left untreated, may lead to permanent vestibular dysfunction.

Common Causes

Vertigo can arise from many different pathophysiologic mechanisms. When we speak specifically about “zoster‑related” vertigo, we are referring to vertigo that occurs as a direct or indirect result of VZV reactivation. Below are the main circumstances that can precipitate this problem, along with other conditions that mimic it.

• Reactivation of varicella‑zoster virus in the vestibular portion of cranial nerve VIII (vestibulocochlear nerve).
• Ramsay Hunt syndrome (herpes zoster oticus): VZV reactivation in the facial nerve (CN VII) that spreads to the ear canal and vestibular apparatus.
• Post‑herpetic neuralgia (PHN) with vestibular involvement: Persistent nerve pain after shingles can irritate adjacent vestibular fibers.
• Concurrent otitis media or otitis externa: Inflammation of the middle or outer ear may facilitate viral spread to vestibular structures.
• Immunosuppression: HIV, chemotherapy, organ transplantation, or high‑dose steroids increase the risk of severe VZV reactivation.
• Advanced age (≥60 years): The immune system’s waning ability makes older adults more vulnerable to shingles complications.
• Diabetes mellitus: Hyperglycemia impairs cellular immunity, predisposing to more aggressive VZV disease.
• Trauma to the ear or skull base: Physical injury can disrupt the blood‑nerve barrier, allowing latent VZV to reactivate locally.
• Other viral infections: Co‑infection with influenza or COVID‑19 may weaken the immune response, increasing the chance of VZV re‑activation.
• Stressful life events or severe emotional stress: Stress hormones can transiently depress immune surveillance, setting the stage for a shingles flare.

Associated Symptoms

Because the vestibular system works closely with the auditory system and the facial nerve, patients with zoster‑related vertigo often report a cluster of additional signs.

• Dizziness or a spinning sensation that worsens with head movement.
• Nausea and vomiting.
• Unsteady gait or difficulty walking straight.
• Ear pain (otalgia) or a burning sensation in the ear canal.
• Rash that follows a dermatomal pattern, typically on the ear, scalp, or behind the ear; the rash may be vesicular and crust over.
• Hearing changes – muffled hearing, tinnitus (ringing), or sudden sensorineural hearing loss.
• Facial muscle weakness or drooping (if CN VII is involved).
• Ear fullness or a feeling of pressure.
• Post‑herpetic neuralgia: persistent burning or stabbing pain after the rash clears.

These symptoms usually appear within a few days to two weeks after the shingles rash begins, but in some cases vertigo can be the first sign, prompting clinicians to look for subtle skin changes.

When to See a Doctor

Prompt medical evaluation is essential to limit nerve damage and improve recovery. Seek care if you experience any of the following:

• Sudden onset of severe vertigo that lasts more than 24 hours.
• Vertigo accompanied by a painful rash in a band‑like distribution on the head or ear.
• Hearing loss, ringing in the ears, or ear drainage.
• Facial weakness, drooping, or difficulty closing the eye on one side.
• Persistent vomiting or inability to keep fluids down for >12 hours.
• New‑onset double vision, slurred speech, or weakness in the arms/legs (signs of a broader neurological problem).
• Symptoms that do not improve after 48 hours of home care.

Diagnosis

Diagnosing zoster‑related vertigo involves a combination of clinical history, physical examination, and selective testing.

1. Detailed History

• Timing of rash vs. vertigo onset.
• Past episodes of shingles or chickenpox.
• Immunization status (shingles vaccine) and immunosuppressive conditions.
• Medications, especially steroids or chemotherapy.

2. Physical Examination

• Otoscopic exam: Look for vesicles, crusting, or erythema in the ear canal.
• Neurological exam: Test cranial nerves, especially facial nerve (CN VII) and vestibulocochlear nerve (CN VIII).
• Bedside vestibular tests: Dix‑Hallpike maneuver, head‑impulse test, and Romberg/performance on foam.

3. Audiology & Vestibular Testing

• Pure‑tone audiometry to assess hearing loss.
• Electronystagmography (ENG) or video‑head‑impulse testing (vHIT) to document vestibular hypofunction.
• Caloric testing if detailed vestibular function is needed.

4. Laboratory & Imaging (when indicated)

• Polymerase chain reaction (PCR) of vesicular fluid: Detects VZV DNA and confirms viral involvement.
• Serology: VZV IgM/IgG may help in ambiguous cases.
• MRI of the brain and internal auditory canals: Rules out stroke, tumor, or demyelinating disease when neurologic red flags are present.

5. Differential Diagnosis

Clinicians must distinguish zoster‑related vertigo from other causes such as BPPV, Meniere’s disease, vestibular migraine, acoustic neuroma, and central causes (stroke, multiple sclerosis). The presence of a dermatomal rash and PCR confirmation are the hallmarks that point to VZV.

Treatment Options

Management focuses on three goals: (1) suppress the viral infection, (2) reduce inflammation and pain, and (3) promote vestibular compensation.

Antiviral Therapy

• Acyclovir, valacyclovir, or famciclovir: Initiated within 72 hours of rash onset. Typical adult dosing is valacyclovir 1 g three times daily for 7 days.
• Early treatment shortens the duration of vertigo and lowers the risk of permanent vestibular loss (CDC, 2022).

Corticosteroids

• Oral prednisone (e.g., 60 mg/day tapered over 10‑14 days) can reduce nerve inflammation, especially when facial nerve involvement is present (Ramsay Hunt syndrome).
• Use is weighed against the risk of immunosuppression; contraindicated in uncontrolled diabetes or severe infection.

Pain Management

• Gabapentin or pregabalin for neuropathic pain.
• Topical lidocaine patches for localized ear pain.
• Over‑the‑counter NSAIDs (ibuprofen, naproxen) for mild discomfort.

Vertigo‑Specific Therapies

• Vestibular Rehabilitation Therapy (VRT): Tailored exercises that improve gaze stabilization, balance, and habituation. Starts once acute symptoms are under control.
• Antiemetics: Meclizine, dimenhydrinate, or ondansetron for severe nausea.
• Hydration & Salt Management: Adequate fluids and a low‑salt diet can reduce associated nausea.

Supportive Home Care

• Rest in a quiet, well‑lit room; avoid rapid head movements.
• Use a firm bedside rail or walker if balance is poor.
• Apply cool compresses to the rash; keep the area clean and dry.
• Consider the shingles vaccine (Shingrix) after recovery to prevent recurrence.

Prevention Tips

Because the condition stems from VZV reactivation, preventing shingles is the most effective strategy.

• Vaccination: Shingrix (recombinant zoster vaccine) is >90 % effective at preventing shingles and its complications in adults ≥50 years. A two‑dose series is recommended by the CDC and WHO.
• Maintain a healthy immune system: Balanced diet, regular exercise, adequate sleep, and stress‑reduction techniques.
• Control chronic diseases: Keep diabetes, hypertension, and HIV well‑managed to preserve immune competence.
• Avoid smoking and excess alcohol: Both impair immune function.
• Prompt treatment of initial shingles rash: Early antiviral therapy reduces the risk of post‑herpetic complications, including vestibular involvement.
• For immunocompromised patients, discuss prophylactic antiviral regimens with a specialist.

Emergency Warning Signs

Key Take‑aways

Zoster‑related vertigo is a relatively rare but potentially disabling complication of shingles. Early recognition—especially the combination of a dermatomal rash with dizziness—allows timely antiviral and anti‑inflammatory treatment, which greatly improves outcomes. Patients should seek care promptly if vertigo is severe, prolonged, or accompanied by hearing loss, facial weakness, or neurologic changes. Vaccination, good immune health, and rapid treatment of shingles are the cornerstones of prevention.

References: CDC. “Shingles (Herpes Zoster).” 2022.
Mayo Clinic. “Vertigo.” 2023.
NIH National Institute on Deafness and Other Communication Disorders. “Vestibular Disorders.” 2022.
Cleveland Clinic. “Ramsay Hunt Syndrome.” 2024.
WHO. “Zoster vaccine: recommendations.” 2021.
Kuo CL et al. “Antiviral therapy for vestibular neuritis: a systematic review.” *J Neurol* 2023.

```